Effects of ropinirole on motor behavior in MPTP-treated common marmosets

Pharmacology Biochemistry and Behavior

Volumn 67, Issue 1, 2000, Pages 121-129

  Fukuzaki, Koichiro ^a   Kamenosono, Takeshi ^a   Kitazumi, Kazuhiro ^b   Nagata, Ryoichi ^a  

^a SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

^b SmithKline Beecham Seiyaku KK   (Japan)

Author keywords

Akinesia; Bromocriptine; Common marmosets; L DOPA; Locomotion; MPTP; Parkinson's disease; Ropinirole

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; BROMOCRIPTINE; CARBOXYMETHYLCELLULOSE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; ROPINIROLE;

AKINESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; DRUG POTENTIATION; FEMALE; LOCOMOTION; MALE; MARMOSET; MOTOR DYSFUNCTION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; RATING SCALE;

ANIMALS; ANTIPARKINSON AGENTS; BROMOCRIPTINE; CALLITHRIX; DOPAMINE AGONISTS; FEMALE; INDOLES; LEVODOPA; MALE; MOTOR ACTIVITY; MPTP POISONING; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 0033661772     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(00)00305-1     Document Type: Article

References (36)

1. Oxygen free radicals and Parkinson's disease
2. Behavioral involvement of central dopamine D1 and D2 receptors in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned parkinsonian cynomolgus monkeys
3. Protective effects of pergolide on dopamine levels in the 6-hydroxydopamine-lesioned mouse brain
4. Classification of drugs according to receptor binding profiles
5. Monoamine oxidase, hydrogen peroxide, and Parkinson's disease
6. 3 and D(4,4) receptors in functional studies using microphysiometry
7. 3 and D(4,4) receptors expressed in Chinese hamster ovaries
8. 2-receptor agonist
9. Preclinical pharmacology of ropinirole (SK and F101468-A) a novel dopamine D2 agonist
10. Adverse effects of levodopa
11. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease
12. The effects of bromocriptine on pre-synaptic and post-synaptic α-adrenoceptors in the mouse vas deferens
13. Effect of LY 171555 and CY 208-243 on tremor suppression in the MPTP monkey model of parkinsonism
14. On-off fluctuations in Parkinson's disease: A clinical and neuropharmacological study
15. Effect of the dopamine D-1 antagonist SCH 23390 on rotational behaviour induced by apomorphine and pergolide in 6-hydroxy-dopamine denervated rats
16. 3 receptors in the basal ganglia of the common marmoset and following MPTP and L-DOPA treatment
17. Treatment of Parkinson's disease with novel dopamine D2 agonist SK and F 101468
18. Ropinirole (SK and F 101468) in the treatment of Parkinson's disease
19. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study
20. Ropinirole: A dopamine agonist for the treatment of Parkinson's disease
21. The selectivity of some ergot derivatives for α1 and α2-adrenoceptors of rat cerebral cortex
22. Effects of bifemelane on parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset
23. Antiparkinsonian agents applied in the treatment of Parkinson's disease or are under investigation for patients or model animals
24. Lisuride infusion pump: A device for the treatment of motor fluctuations in Parkinson's disease
25. Possible neuroprotective therapy for Parkinson's desease
26. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus)
27. Effects of repeated treatment with L-DOPA, bromocriptine and ropinirole in drug naive MPTP-treated common marmosets
28. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-DOPA in the MPTP-treated marmoset
29. Parkinsonism with 'on-off' phenomena. Intravenous treatment with levodopa after major abdominal surgery
30. Molecular biology of dopamine receptors
31. 3) as a target for neuroleptics
32. Subcutaneous apomorphine in parkinsonian on-off oscillations
33. 1
34. Pergolide mesylate: Four years experience in Parkinson's disease
35. 4 receptor with high affinity for dopamine the antipsychotic clozapine
36. Ropinirole without levodopa in Parkinson's disease